Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
- Trial name
- NCT02603393
- Testing
- QVA149, Tiotropium, Salmeterol/fluticasone
- Where
- 167 sites in Argentina, Austria and 19 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to investigate the efficacy and safety of Ba679BR powder inhalation during the continuous once/day administration to the patients with COPD using oxitropium bromide (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02172807
- Testing
- Tiotropium low, Tiotropium high, Oxitropium
- Volunteers
- 201 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the long -term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo in patients with COPD.
- Trial name
- COPD (NCT02172287)
- Testing
- Tiotropium (Ba679 BR), Salmeterol
- Volunteers
- 623 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
- Trial name
- NCT00832611
- Testing
- Arteriovenous Fistula (ROX AC1)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- ROX Medical, Inc.
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care…
- Trial name
- NCT07035652
- Testing
- XH-S004 20 mg, 40 mg or 60 mg
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Pulmonary Disease, Chronic Obstructive
A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients…
- Trial name
- NCT00144326
- Testing
- Tiotropium Bromide
- Where
- 27 sites in Canada, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
The overall objective of this study was to assess the efficacy and safety of GP MDI relative to placebo in Japanese subjects with moderate to severe COPD.
- Trial name
- NCT03256552
- Testing
- Glycopyrronium MDI 28.8 micrograms, Glycopyrronium MDI 14.4 micrograms, Glycopyrronium MDI 7.2 micrograms
- Where
- 18 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study
COPD is a lung disease in which the lung is damaged, making it hard to breathe. In COPD, the airways/tubes that carry air in and out of the lungs are partly obstructed, making it difficult to get air in and out.
- Trial name
- COPD (NCT00883584)
- Testing
- IMD-1041
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Institute of Medicinal Molecular Design, Inc.
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113373 (NCT01313650)
- Testing
- 62.5/25mcg, 62.5mcg, 25mcg
- Where
- 165 sites in United States, Bulgaria and 11 more
- Volunteers
- 1,538 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
This study is designed to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness compared with Tiotropium QD over 12 week treatment period in…
- Trial name
- NCT01395888
- Testing
- fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI), Tiotropium
- Where
- 55 sites in Argentina, France and 5 more
- Volunteers
- 260 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
To evaluate the safety and pharmacokinetics of different dose roflumilast in China COPD patient.
- Trial name
- NCT02671942
- Testing
- Roflumilast
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD
A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD
The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.
- Trial name
- NCT00308191
- Testing
- Formoterol Fumarate, Tiotropium Bromide
- Where
- 17 sites in United States
- Volunteers
- 128 people
- Sponsor
- Dey
Pulmonary Emphysema
Post Market Registry Study of the AeriSeal System
Obtain and analyze medical record data on patients with advanced emphysema who receive treatment with the AeriSeal System to better understand safety and effectiveness in the post-market setting; Provide participating physicians…
- Trial name
- NCT01520064
- Where
- 12 sites in Germany, Israel
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This pharmacodynamic and pharmacokinetic dose-ranging study aims to determine the optimal dose of tiotropium inhaled as a solution from a Respimat device once a day for three weeks in patients with COPD.
- Trial name
- NCT02175342
- Testing
- Tiotropium 0.625 mcg/puff, Tiotropium 1.25 mcg/puff, Tiotropium 2.5 mcg/puff
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of the study was to demonstrate the superiority of Foster® 100/6 (two puffs b.i.d.) versus Seretide® 500/50 (one inhalation b.i.d.), in terms of pulmonary function (AUC0-30min standardized by time of change…
- Trial name
- FUTURE (NCT01245569)
- Testing
- Beclomethasone Dipropionate - Formoterol, Fluticasone - Salmeterol
- Where
- 68 sites in Denmark, France and 8 more
- Volunteers
- 419 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.
- Trial name
- NCT00857766
- Testing
- ADVAIR DISKUS™ 250/50mcg
- Where
- 24 sites in United States
- Volunteers
- 249 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy of Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium Bromide Administered Via Dry Powder Inhaler in COPD
- Trial name
- TRI-D (NCT03590379)
- Testing
- CHF 5993 DPI, CHF5993 pMDI, CHF 1535 pMDI
- Where
- Bulgaria
- Volunteers
- 366 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.